REG - Cizzle Biotechnology - Result of AGM

Cizzle Biotechnology HoldingsAnnouncement

30/06/2025 14:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nRSd0234Pa&default-theme=true

RNS Number : 0234P  Cizzle Biotechnology Holdings PLC  30 June 2025

30 June 2025

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Result of AGM

Cizzle Biotechnology, the UK based diagnostics developer, announces that at
the Annual General Meeting ("AGM") of the Company held earlier today, all
resolutions were voted on by a show of hands and were passed.

The proxy votes cast in respect of the resolutions were as follows:

 

 Resolution                                                                     For*                 Against            Votes withheld
                                                                                Total votes  %       Total votes  %
 1.   To receive the Company's annual report and accounts for the year ended    113,796,829  100.00  0            0.00  0
 31 December 2024
 2.   To approve the Directors' Remuneration Policy                             113,434,973  99.68   359,286      0.32  2,570
 3.   To approve the 2024 Remuneration Report                                   113,529,139  99.77   265,120      0.23  2,570
 4.   To re-appoint Edwin Matthew Bower as a Director of the Company            113,762,519  99.97   34,200       0.03  110
 5.   To re-appoint Allan John Syms as a Director of the Company                113,762,519  100.00  0            0.00  34,310
 6.   To re-appoint PKF Littlejohn LLP as auditor of the Company                113,696,829  99.91   100,000      0.09  0
 7.   To authorise the Directors to determine the auditor's remuneration        113,796,709  100.00  110          0.00  10
 8.   Authorises the Directors to allot shares in the Company or to grant       113,796,719  100.00  110          0.00  0
 rights to subscribe for, or to convert any security into, shares in the
 Company
 9.   Authorise the Directors to allot equity securities disapplying            112,297,509  98.68   1,499,310    1.32  10
 pre-emption rights
 10. That General Meetings may be called on not less than 14 days' notice       113,796,829  100.00  0            0.00  0

Notes:

*"Votes For" include votes giving the Chairman's discretion.

Enquiries:

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited                               +44(0) 20 3328 5656
 John Depasquale / Piers Shimwell (Corporate Finance)
 Amrit Nahal (Sales and Corporate Broking)

 

 IFC Advisory Limited          +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Staton

 

About Cizzle Biotechnology

Based on the pioneering work of Professor Coverley and colleagues, on a
naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B
biomarker is highly associated with the presence of early-stage cancer. The
company has developed CIZ1B into a non-invasive, cost-effective blood test to
help in the early detection of lung cancer and has now entered commercial
royalty-bearing arrangements to license its proprietary technology, and into
collaborations with centres of excellence in cancer care.  Cizzle was
admitted to the Standard segment of the main market of the London Stock
Exchange in May 2021.

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSDIFESEISELM